Categories: News

Spheryx Introduces xSight, a Revolutionary Particle Characterization Instrument, with Live Demonstrations at the 10th Annual PEGS Boston, April 8-12, 2019.

NEW YORK, April 4, 2019 /PRNewswire/ — Spheryx, Inc. will demonstrate xSight, their particle characterization instrument at PEGS Boston, April 8-12, 2019, in the Exhibit Hall at Seaport World Trade Center, Booth 500. PEGS Boston is the largest biologics event, drawing over 2,600 international participants interested in collaborating and sharing best practices in biologic therapeutics. xSight, uses Spheryx’s proprietary technology, Total Holographic Characterization®, to detect, count and characterize sub-visible particles in complex heterogeneous mixtures, including protein aggregates, a known safety hazard in biologic pharmaceuticals.

Additionally, Spheryx was selected from 4,500 applicants to participate in the Hello Tomorrow Global Summit in Paris, an annual competition to showcase start-ups that solve an unmet industrial, environmental or societal need.

Spheryx announces the addition of Dr. Ross Boltyanskiy in the roll of Senior Scientist. Dr. Boltyanskiy received his PhD in physics from Yale University, and was a Postdoctoral Research Fellow at Memorial Sloan Kettering. Dr. Laura Phillips, President and CEO, stated, “We are delighted to have Dr. Boltyanskiy on board. With his expertise in microscopy, opto-mechanical technology and data visualization, he is a welcome addition to the Spheryx team.”

About Spheryx, Inc.
Spheryx, Inc. is a privately held analytical services and instruments company providing Total Holographic Characterization® of colloidal materials. Spheryx’s proprietary technology uses holographic video microscopy to characterize each particle in colloidal dispersions and multi-component colloidal mixtures, offering unprecedented insights into these materials’ characteristics. Applications include R&D, quality assurance and manufacturing process control across a broad spectrum of industries, where characterization of colloids can enhance innovation, improve safety and reduce costs. For more information: https://www.spheryx.solutions/

Note: This news release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or result to differ materially.

Contact: Laura Philips, CEO
lphilips@spheryx.solutions  
607-738-0100

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/spheryx-introduces-xsight-a-revolutionary-particle-characterization-instrument-with-live-demonstrations-at-the-10th-annual-pegs-boston-april-8-12-2019-300824410.html

SOURCE Spheryx, Inc.

Staff

Recent Posts

HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference

HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia…

45 minutes ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…

46 minutes ago

The National Children’s Cancer Society Awarded $1,000 Grant From Kars4Kids

This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…

49 minutes ago

Honeycomb Clinic Positions for Public Offering

Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…

49 minutes ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"…

49 minutes ago

Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson’s Disease

MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the…

50 minutes ago